| Patents for C07K 5 - Peptides having up to four amino acids in a fully defined sequence; Derivatives thereof (30,692) |
|---|
| 01/16/2002 | EP1171452A2 Pyrrolidincarbolylamino cyclic disulfides as vcam-vla4 antagonists |
| 01/16/2002 | EP1171166A1 Benzodiazepine derivatives for imaging thrombi |
| 01/16/2002 | EP1171152A1 vMIP-II PEPTIDE ANTAGONISTS OF CXCR4 |
| 01/16/2002 | EP1170998A2 Transformed cells useful for the control of pests |
| 01/16/2002 | EP0932617B1 Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
| 01/16/2002 | EP0782580A4 Parallel selex |
| 01/16/2002 | CN1331083A Memory-improving peptides and their application |
| 01/15/2002 | US6339173 For interfering with protein expression in a cell; useful in lipid aggregates for the delivery of macromolecules into cells |
| 01/15/2002 | US6339160 For therapy of tumoral growth and metastatization, aterosclerosis, multiple sclerosis, alzheimer's disease, osteoporosis, hypertension, rheumatoid arthritis and other inflammatory diseases |
| 01/15/2002 | US6339069 Administering formulation comprising pharmaceutically acceptable carrier; and, liposome comprising a bioactive agent and a lipid component, the lipid component comprising a peptide-lipid conjugate |
| 01/15/2002 | US6339062 Retroinverso polypeptides that mimic or inhibit thrombospondin activity |
| 01/10/2002 | WO2002002596A2 Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them |
| 01/10/2002 | WO2002002592A1 Memory-enhancing peptides and the use thereof |
| 01/10/2002 | WO2002002591A2 Peptides for use in culture media |
| 01/10/2002 | WO2002002556A2 AZA-BRIDGED-BICYCLIC AMINO ACID DERIVATIVES AS α4 INTEGRIN ANTAGONISTS |
| 01/10/2002 | WO2001025410A3 DIAGNOSTIC PROBES AND THERAPEUTICS TARGETING uPA AND uPAR |
| 01/10/2002 | US20020004512 Sexual disorders |
| 01/10/2002 | US20020004247 Assay method |
| 01/10/2002 | US20020004202 In vivo screen using chemical inducers of dimerization |
| 01/10/2002 | CA2415088A1 Aza-bridged-bicyclic amino acid derivatives as .alpha.4 integrin antagonists |
| 01/09/2002 | EP1170300A1 Method for modification of recombinant polypeptides |
| 01/09/2002 | EP1169470A1 Methods and reagents for determining enzyme substrate specificity, and uses related thereto |
| 01/09/2002 | EP1169339A1 Macrocyclic peptides inhibiting the hepatitis c virus ns3 protease |
| 01/09/2002 | EP1169338A2 Low-molecular inhibitors of complement proteases |
| 01/09/2002 | EP1169318A1 Prodrugs of thrombin inhibitors |
| 01/09/2002 | EP1169315A2 Method for producing amidines |
| 01/09/2002 | EP1169298A2 Pharmaceutical compounds |
| 01/09/2002 | CN1330661A Procollagen C-proteinase inhibitors |
| 01/09/2002 | CN1330660A Cycle tetrapeptide compound and their use |
| 01/09/2002 | CN1330637A Compounds useful in treatment of infammatory diseases |
| 01/09/2002 | CN1330073A Peptide nucleic acid derivatives, intermediate for preparing them and medicinal composition containing them |
| 01/09/2002 | CN1077439C Labeled chemotactic peptides to image focal sites of infection or inflammation |
| 01/08/2002 | US6337394 N-acyl-heterocycle-carboxyamides that are n-substituted with amidino-substituted rings; competitive inhibitors of thrombin; anticoagulants |
| 01/08/2002 | US6337343 Amino acid derivatives |
| 01/08/2002 | US6337319 μ-Selective opioid peptides |
| 01/03/2002 | WO2002000684A2 Method of obtaining peptides with tissue-specific activity and pharmaceutical compositions on their basis |
| 01/03/2002 | WO2002000263A2 Tripeptide prodrug compounds |
| 01/03/2002 | WO2001070275A3 Polyglutamic acid-camptothecin conjugates and methods of preparation |
| 01/03/2002 | WO2001066564A3 Gamma-secretase inhibitors |
| 01/03/2002 | US20020002283 Process for preparing growth hormone secretagogues |
| 01/03/2002 | US20020002268 Antithrombotic azacycloalkylalkanoyl peptides and pseudopeptides |
| 01/03/2002 | US20020002165 Growth hormone secretagogues useful for treatment/prevention of osteoporosis |
| 01/03/2002 | US20020002163 1,4-benzodiazepinones and their uses as CCK antagonists |
| 01/03/2002 | US20020002138 For use in treatment of diseases associated with reduced levels of growth hormone |
| 01/03/2002 | US20020001652 Roller compaction; reducing particle size; dustless, free-flowing powder |
| 01/03/2002 | US20020001591 Compositions for the delivery of antigens |
| 01/03/2002 | DE10027514A1 Liganden von Integrinrezeptoren Ligands of integrin |
| 01/03/2002 | CA2411545A1 Tripeptide prodrug compounds |
| 01/02/2002 | EP1166781A1 Proteasome inhibitors |
| 01/02/2002 | EP1166778A2 The use of growth hormone scretagogues to treat systemic lupus erythematosus and inflammatory bowel disease |
| 01/02/2002 | EP1165799A1 Microbiological production method for alpha-l-aspartyl-l-phenylalanine |
| 01/02/2002 | EP1165601A2 Prodrugs of thrombin inhibitors |
| 01/02/2002 | EP1165541A1 Dimeric compounds and as inhibitors of neuraminidase |
| 01/02/2002 | EP1165506A1 Substituted azetidin-2-ones as cysteine protease inhibitors |
| 01/02/2002 | EP1165492A1 Hydroxyphenyl derivatives with hiv integrase inhibitory properties |
| 01/02/2002 | EP1165490A1 Substituted 2-aminobenzamide caspase inhibitors and the use thereof |
| 01/02/2002 | EP1165120A2 A uro-genital condition treatment system |
| 01/02/2002 | EP1135151A4 Peptoid and nonpeptoid containing alpha-keto oxadiazoles as serine protease inhibitors |
| 01/02/2002 | EP0994893B1 Selective factor xa inhibitors containing a fused azepinone structure |
| 01/02/2002 | EP0941104A4 Peptide synthesis with sulfonyl protecting groups |
| 01/02/2002 | EP0722457B1 Compounds modifying serotoninergic transmission, diagnostic and therapeutic applications |
| 01/02/2002 | CN1329665A Gluocoamylases with N-terminal extensions |
| 01/01/2002 | US6335461 Extracting with specified organic solvent from aqueous reaction solution or slurry, further purifying by crystallization, chromatography, extraction or absorption on activated charcoal |
| 01/01/2002 | US6335460 Treating retroviral infections, including human immunodeficiency virus, and aids |
| 01/01/2002 | US6335453 Process for preparing pharmacologically acceptable salt of N-(1(S)-ethoxycarbonyl-3-phenylpropyl)-L-alanyl amino acids |
| 01/01/2002 | US6335443 Chemical synthesis of exochelins |
| 01/01/2002 | US6335360 Indoline-2-carboxylic amide derivatives; obesity, eating and psychological disorders |
| 01/01/2002 | US6335320 Method of treating fibrotic conditions |
| 01/01/2002 | US6334996 Radiolabels for targeting specific diagnostic pharmaceuticals |
| 01/01/2002 | CA1341330C Substituted acyl dertivatives of 1,2,3,4-tetrahydroisquinoline-3-carboxylic acids |
| 12/29/2001 | CA2351897A1 Use of growth hormone secretagogues for treatment of physical performance decline |
| 12/27/2001 | WO2001098540A2 Recombination modulators and methods for their production and use |
| 12/27/2001 | WO2001098367A2 Neuroactive peptides for treatment of hypoxia and related conditions |
| 12/27/2001 | WO2001098362A2 Chemically-modified antimicrobial peptides, compositions and methods of production and use |
| 12/27/2001 | WO2001098294A2 Vitronectin receptor antagonist pharmaceuticals for use in combination therapy |
| 12/27/2001 | WO2001097861A2 Vitronectin receptor antagonist pharmaceuticals |
| 12/27/2001 | US20010056179 Selective linear peptides with melanocortin-4 receptor (MC4-R) agonist activity |
| 12/27/2001 | US20010056178 Inhibitors of protein synthesis, cell growth and tumorigenesis, and enhancers of apoptosis |
| 12/27/2001 | CA2413974A1 Neuroactive peptides for treatment of hypoxia and related conditions |
| 12/27/2001 | CA2413957A1 Vitronectin receptor antagonist pharmaceuticals for use in combination therapy |
| 12/27/2001 | CA2412849A1 Vitronectin receptor antagonist pharmaceuticals for use in combination therapy |
| 12/27/2001 | CA2412513A1 Modulators of recombination and methods for producing and using the same |
| 12/27/2001 | CA2412011A1 Chemically-modified antimicrobial peptides, compositions and methods of production and use |
| 12/25/2001 | US6333403 Nucleotide sequences coding polypeptide associated with tumors; for use in diagnosis and treatment of tumors |
| 12/25/2001 | US6333395 Exhibit anti-membrane fusion capability, antiviral activity, such as the ability to inhibit hiv transmission to uninfected cells |
| 12/25/2001 | US6333321 For therapy of unstable angina, refractory angina, myocardial infarction, transient ischemic attacks, thrombotic stroke, embolic stroke, disseminated intravascular coagulation, deep venous thrombosis, pulmonary embolism, and reocclusion |
| 12/25/2001 | US6333176 Enzymatic cleavage of c-terminal amino group from peptide amide, deamination with peptide amidase, incubation and inoculation |
| 12/20/2001 | WO2001097217A2 Optical storage using materials comprising chromophore oligomers which can undergo cycloaddition |
| 12/20/2001 | WO2001096369A1 Gluthione analogues and their use as antioxidants |
| 12/20/2001 | WO2001096367A1 Melphalan derivatives and their use as cancer chemotherapeutic drugs |
| 12/20/2001 | WO2001096364A2 Peptides that stimulate cell survival and axon regeneration |
| 12/20/2001 | WO2001096300A1 Growth hormone secretagogues |
| 12/20/2001 | WO2001096286A2 Urokinase inhibitors |
| 12/20/2001 | WO2001095943A2 Prodrug compounds with an oligopeptide having an isoleucine residue |
| 12/20/2001 | WO2001095932A1 A COMBINATION PRODUCT COMPRISING MELAGATRAN AND A FACTOR VIIa INHIBITOR |
| 12/20/2001 | WO2001027242A3 Methods for identifying inhibitors of methionine aminopeptidases |
| 12/20/2001 | DE10029015A1 Coagulation Factor Xa inhibitor, useful for treatment, prophylaxis or diagnosis of thromboembolic disease, comprising acylated 3- or 4-amidino-benzylamine derivative |
| 12/20/2001 | DE10029014A1 Urokinase inhibitor, useful for treatment, prophylaxis or diagnosis of thromboembolic disease, comprising acylated 3- or 4-amidino-benzylamine derivative |
| 12/20/2001 | DE10028402A1 New pyridinylamino-alkanoyl-glycyl-beta-alanine derivatives, are integrin inhibitors useful for treating, e.g. thrombosis, cardiac infarction, coronary heart disease, inflammation, tumors, osteoporosis or restenosis |
| 12/20/2001 | CA2413149A1 Prodrug compounds with isoleucine |